Professor René C.-Gaudreault receives CIHR funding
SOVAR is proud to announce that Dr. René C.-Gaudreault of Centre hospitalier universitaire de Québec (CHUQ) is the recipient of $160,000 in funding under the Canadian Institutes of Health Research (CIHR) Proof of Principle program (POP-Phase 1).
This funding will be used to ascertain the anticancer activity of synthetic molecules in the imidazolidone family. These agents have potential applications in the treatment of breast, colon, and skin cancers.
The POP program is very competitive. It is specifically aimed at technologies with solid scientific underpinnings and high commercial potential.
This funding will further development of the technology, enhancing its value and preparing for its eventual introduction to market.